Welcome to our dedicated page for Scynexis SEC filings (Ticker: SCYX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SCYNEXIS, Inc. (SCYX) SEC filings page on Stock Titan provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. These filings offer detailed information on SCYNEXIS’s antifungal drug development programs, its exclusive license agreement with GSK for ibrexafungerp and BREXAFEMME, financial condition, governance, and risk factors.
Investors can review annual reports on Form 10-K and quarterly reports on Form 10-Q for comprehensive discussions of the company’s fungerp platform, including ibrexafungerp and second-generation candidate SCY-247, as well as descriptions of clinical programs, collaboration terms, and revenue recognition from the GSK license agreement. These periodic reports also summarize research and development expenses, selling, general and administrative costs, cash balances, and other key financial metrics.
Current reports on Form 8-K capture material events such as the binding memorandum of understanding with GSK resolving the disagreement over the Phase 3 MARIO study, associated payments, and updates on the transfer of the BREXAFEMME New Drug Application. Other 8-K filings describe Nasdaq listing notices, annual meeting voting results, and similar corporate developments.
This page also surfaces proxy statements and related materials that address director elections, advisory votes on executive compensation, and auditor ratification. Together, these documents help users understand SCYNEXIS’s governance structure and shareholder decisions.
Stock Titan enhances these filings with AI-powered summaries that explain complex sections in plain language, highlight key changes from prior periods, and point out items such as license agreement terms, clinical program disclosures, and capital structure details. Users can quickly scan new 10-K, 10-Q, and 8-K filings, as well as track warrant liabilities, deferred revenue, and other line items that SCYNEXIS reports in its financial statements.
SCYNEXIS, Inc. focuses on severe fungal infections, built around its novel "fungerp" antifungal platform. Its first drug, ibrexafungerp (BREXAFEMME), is licensed globally to GSK for vulvovaginal candidiasis and recurrent VVC.
The lead wholly owned asset, SCY-247, completed single and multiple ascending dose Phase 1 oral studies in 88 healthy subjects, showing good tolerability and generally dose‑proportional pharmacokinetics. An intravenous Phase 1 trial began in early 2026, with a Phase 2 invasive candidiasis study planned for 2026.
Under a GSK license, SCYNEXIS ran the MARIO Phase 3 ibrexafungerp study, then agreed in an October 2025 memorandum to wind it down, receiving one‑time payments totaling $24.8 million in addition to a $10.0 million development milestone earlier in 2025.
SCYNEXIS reported an accumulated deficit of about $385.1 million and cash, cash equivalents and investments of $56.3 million as of December 31, 2025. The company expects continuing operating losses and will require substantial additional capital while it advances SCY‑247 and evaluates further partnering and in‑licensing opportunities.
Avidity Partners and affiliates reported a significant passive stake in Scynexis, Inc. common stock on Schedule 13G/A (Amendment No. 8). The group, including Avidity Partners Management LP and Michael Gregory, is shown as beneficially owning 4,426,565 shares, representing 9.9% of Scynexis’s common stock as of the event date.
The holdings are largely split between Avidity Master Fund LP with 852,750 shares (2.0% of the class) and Avidity Private Master Fund I LP with 3,573,815 shares (8.1% of the class), over which the reporting persons share voting and dispositive power. They certify the securities were not acquired to change or influence control of Scynexis.
SCYNEXIS, Inc. received an amended Schedule 13G/A from Kingdon Capital Management, L.L.C. and Mark Kingdon reporting that they now beneficially own 0 shares of the company’s common stock, or 0% of the class, as of December 31, 2025.
They report no sole or shared voting or dispositive power over any SCYNEXIS shares and indicate ownership of 5 percent or less of the class. They also certify that any securities previously held were not acquired to change or influence control of the company.
SCYNEXIS Inc. reported an equity award to its Chief Financial Officer. On 01/29/2026, CFO Macleod Ivor received 129,833 shares of common stock at a price of $0, reported as an acquisition.
These shares represent restricted stock units that vest in three equal annual installments starting February 28, 2026. Following this grant, the officer beneficially owns 398,529 shares directly.
SCYNEXIS Inc. granted equity compensation to its Chief Legal Officer, Scott Sukenick. On January 29, 2026, he received 129,833 shares of common stock at a price of $0 per share in the form of restricted stock units. These units vest one third per year over three years starting February 28, 2026, providing time-based retention incentives. Following this grant, he beneficially owns 574,539 shares of SCYNEXIS common stock in direct ownership.
SCYNEXIS Inc. reported an equity award to its CEO, David Angulo Gonzalez. On January 29, 2026, he received 391,333 shares of common stock as a stock-based grant priced at $0 per share, structured as restricted stock units.
After this award, he beneficially owned 1,244,431 shares of SCYNEXIS common stock in total. The restricted stock units vest in three equal annual installments, with vesting measured from February 28, 2026, which ties the award to multi‑year service and performance with the company.
Federated Hermes, Inc. and related reporting persons filed an amended Schedule 13G/A reporting beneficial ownership of 3,533,250 shares of SCYNEXIS, INC. common stock, representing 8.42% of the class as of 12/31/2025. Federated Hermes has sole voting and dispositive power over these shares, while the Voting Shares Irrevocable Trust reports the same sole voting and dispositive power.
Individuals Thomas R. Donahue, Ann C. Donahue, and J. Christopher Donahue each report shared voting and shared dispositive power over the same 3,533,250 shares and the same 8.42% stake. The filers state the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of SCYNEXIS. They also expressly disclaim beneficial ownership of securities held by the managed funds.
SCYNEXIS (SCYX) reported Q3 2025 results. License revenue was $334,000, down from $660,000 a year ago. Operating expenses fell to $8.7 million, led by lower R&D at $5.5 million and SG&A of $3.3 million. The company posted a net loss of $8.6 million, or $0.17 per share, including a $0.6 million loss from warrant fair value adjustments.
Cash, cash equivalents, and short-term investments totaled $37.9 million as of September 30, 2025. Convertible notes were repaid at maturity in March 2025, reducing current debt to zero. A $10.0 million license receivable is on the balance sheet tied to the GSK collaboration.
After quarter-end, SCYNEXIS and GSK signed a binding memorandum of understanding under which SCYNEXIS will wind down the MARIO study and receive one-time payments totaling $24.8 million. Other potential milestones and royalties under the GSK license remain unchanged. The company also disclosed a Nasdaq minimum bid price notice received on June 20, 2025, with a compliance period through December 17, 2025.
SCYNEXIS (SCYX) reported an insider transaction on a Form 4. On 10/17/2025, a company Chief Executive Officer and Director acquired 32,500 shares of common stock at $0.76 per share. Following this trade, the insider’s beneficial ownership stands at 853,098 shares, held directly.
The filing notes this total includes 4,000 shares acquired under the 2014 Employee Stock Purchase Plan on 09/05/2025.
SCYNEXIS (SCYX) entered a binding memorandum of understanding with GSK to amend their exclusive license, resolving the prior disagreement over the Phase 3 MARIO study of ibrexafungerp. SCYNEXIS will promptly wind down and terminate the MARIO study and will receive $22 million from GSK, plus an additional $2.3 million in connection with the wind-down and termination activities. SCYNEXIS will not receive additional milestone payments specifically tied to MARIO.
GSK reiterated its commitment to the broader collaboration, including commercialization of BREXAFEMME (ibrexafungerp tablets) for VVC and rVVC. SCYNEXIS continues to progress the transfer of the BREXAFEMME NDA to GSK by the end of 2025. GSK anticipates initiating FDA interactions in 2026 to discuss a U.S. relaunch for VVC and rVVC. Other potential milestones and royalties under the exclusive license remain unchanged.